BioAffinity Technologies Net Worth
BioAffinity Technologies Net Worth Breakdown | BIAFW |
BioAffinity Technologies Net Worth Analysis
BioAffinity Technologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioAffinity Technologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioAffinity Technologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioAffinity Technologies' net worth analysis. One common approach is to calculate BioAffinity Technologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioAffinity Technologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioAffinity Technologies' net worth. This approach calculates the present value of BioAffinity Technologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioAffinity Technologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioAffinity Technologies' net worth. This involves comparing BioAffinity Technologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioAffinity Technologies' net worth relative to its peers.
Enterprise Value |
|
To determine if BioAffinity Technologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioAffinity Technologies' net worth research are outlined below:
| BioAffinity Technologies is way too risky over 90 days horizon | |
| BioAffinity Technologies has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies appears to be risky and price may revert if volatility continues | |
| BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies Warrant has accumulated 1.58 M in total debt. BioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 3.28 M. | |
| bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from businesswire.com: bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of 1.4 Million |
Project BioAffinity Technologies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.19) | (1.25) | |
| Return On Capital Employed | (1.53) | (1.46) | |
| Return On Assets | (0.87) | (0.91) | |
| Return On Equity | (1.88) | (1.79) |
When accessing BioAffinity Technologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioAffinity Technologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioAffinity Technologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioAffinity Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of bioAffinity Technologies Warrant. Check BioAffinity Technologies' Beneish M Score to see the likelihood of BioAffinity Technologies' management manipulating its earnings.
Evaluate BioAffinity Technologies' management efficiency
The company has return on total asset (ROA) of (0.6234) % which means that it has lost $0.6234 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.67) %, meaning that it generated substantial loss on money invested by shareholders. BioAffinity Technologies' management efficiency ratios could be used to measure how well BioAffinity Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.25 in 2025. Return On Capital Employed is likely to climb to -1.46 in 2025. At this time, BioAffinity Technologies' Non Current Assets Total are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 1.20 in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 10 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.50 | 0.52 | |
| Tangible Book Value Per Share | 0.27 | 0.28 | |
| Enterprise Value Over EBITDA | (1.37) | (1.44) | |
| Price Book Value Ratio | 2.38 | 2.50 | |
| Enterprise Value Multiple | (1.37) | (1.44) | |
| Price Fair Value | 2.38 | 2.50 | |
| Enterprise Value | 13.4 M | 12.7 M |
The strategic decisions made by BioAffinity Technologies management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAffinity Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioAffinity Technologies time-series forecasting models is one of many BioAffinity Technologies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioAffinity Technologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
BioAffinity Technologies Earnings per Share Projection vs Actual
BioAffinity Technologies Corporate Management
| Timothy JD | Secretary VP | Profile | |
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Xavier MS | VP Operations | Profile |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.